- Home
- MXCT vs ACRS Comparison
MXCT vs ACRS Comparison
Compare MXCT & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MXCT
- ACRS
- Stock Information
- Founded
- MXCT 1999
- ACRS 2012
- Country
- MXCT United States
- ACRS United States
- Employees
- MXCT N/A
- ACRS N/A
- Industry
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- MXCT Health Care
- ACRS Health Care
- Exchange
- MXCT Nasdaq
- ACRS Nasdaq
- Market Cap
- MXCT 148.2M
- ACRS 165.7M
- IPO Year
- MXCT 2021
- ACRS 2015
- Fundamental
- Price
- MXCT $1.45
- ACRS $1.84
- Analyst Decision
- MXCT Buy
- ACRS Strong Buy
- Analyst Count
- MXCT 4
- ACRS 9
- Target Price
- MXCT $7.50
- ACRS $9.25
- AVG Volume (30 Days)
- MXCT 797.5K
- ACRS 813.5K
- Earning Date
- MXCT 11-05-2025
- ACRS 11-05-2025
- Dividend Yield
- MXCT N/A
- ACRS N/A
- EPS Growth
- MXCT N/A
- ACRS N/A
- EPS
- MXCT N/A
- ACRS N/A
- Revenue
- MXCT $35,754,000.00
- ACRS $16,789,000.00
- Revenue This Year
- MXCT N/A
- ACRS N/A
- Revenue Next Year
- MXCT $14.79
- ACRS N/A
- P/E Ratio
- MXCT N/A
- ACRS N/A
- Revenue Growth
- MXCT N/A
- ACRS N/A
- 52 Week Low
- MXCT $1.26
- ACRS $1.05
- 52 Week High
- MXCT $5.20
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- MXCT 43.25
- ACRS 47.21
- Support Level
- MXCT $1.39
- ACRS $2.01
- Resistance Level
- MXCT $1.49
- ACRS $2.16
- Average True Range (ATR)
- MXCT 0.06
- ACRS 0.11
- MACD
- MXCT 0.04
- ACRS -0.02
- Stochastic Oscillator
- MXCT 76.47
- ACRS 14.86
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.